Prescribing Information
En Español
What do the Experts Say?
Tell A Friend
Find a pharmacy near you by entering your zip code
 

Next Choice® (levonorgestrel), 0.75 mg, is a new emergency contraceptive from Watson that can help women during these unexpected times.

Next Choice is a generic product that is bioequivalent to the two tablet Plan B® product.

  • Composed of progestin-only tablets
  • Contains a simple 2-tablet treatment
  • Safe and well tolerated
  • NDC Number: 52544-0275-36

It is available behind the pharmacy counter and sold under a licensed pharmacist's supervision. Women 16 years of age or younger require a prescription.

Prepare for the unexpected

When used as directed, Next Choice reduces pregnancy risk by as much as 89% when taken within 72 hours of unprotected sex. A study demonstrated efficacy was even greater within 24 hours.1,2 So it is important that your customers have access to emergency contraceptives and educational guidance when it is needed:

  • Stock up today! Make sure that Next Choice is available at your pharmacy so that it can be provided as soon as possible to help a woman’s chance of preventing an unplanned pregnancy1
  • Anticipate your customers’ questions! Educating your patients about emergency contraception can help them better prepare for an unplanned pregnancy! For helpful discussion points to review with your customers, please click here.

Ordering information

To place an order for Next Choice, please contact your wholesaler today or call us at our toll-free number,
866-9WATSON (992-8766).

Important Safety Information

Next Choice® should not be used by women with a known or suspected pregnancy. Women who become pregnant or complain of lower abdominal pain after taking Next Choice should be evaluated for ectopic pregnancy. Next Choice is not effective in terminating an existing pregnancy, and does not protect against STI/HIV. Next Choice may alter the next expected menses, however, if menses is delayed beyond 1 week, pregnancy should be considered. The most common adverse reactions in the clinical trial were menstrual changes (26%), nausea (23%), abdominal pain (18%), fatigue (17%), headache (17%), dizziness (11%), and breast tenderness (11%).

To report side effects of prescription drugs to the FDA, visit fda.gov/medwatch or call 1-800-FDA-1088.

For more information about Next Choice, please call our Medical Communications Department at 866-9WATSON.

This Web site is intended for United States Prescribers, Pharmacists & Consumers.

Plan B® is a registered trademark of Women’s Capital Corporation, a subsidiary of Duramed Pharmaceuticals, Inc.